Intas and Axantia sign an exclusive agreement for Ranibizumab biosimilar in the Middle East
Intas Pharmaceuticals has signed an exclusive license and supply agreement with Axantia Holding, a leading pharmaceutical company in the Middle East for Ranibizumab (biosimilar of Lucentis®). Under the terms of this agreement, Axantia will register, hold the marketing authorization and commercialize Ranibizumab in certain territories including Saudi Arabia, Jordan, Iraq, Lebanon and GCC countries.
Intas has developed a biosimilar of Lucentis®, which is currently under Phase III global trial for submission in major countries including EMA & US.
